HealthDay News — For patients with asthma and allergic rhinitis with/without conjunctivitis (AR/C), treatment with a Timothy grass sublingual immunotherapy tablet (SLIT-tablet) may be safe, results of research published in Allergy indicate.
Using data from eight trials of grass SLIT-tablet in subjects with allergic rhinitis with/without conjunctivitis (AR/C), Jennifer Maloney, MD, of Merck & Co. in Whitehouse Station, N.J., and colleagues pooled data to determine impact. Data were included for 3,314 adults and 881 children, of whom 24% and 31%, respectively, had reported asthma.
No serious local allergic swellings or serious allergic reactions among SLIT-tablet-treated individuals with asthma were seen, noted the investigators. SLIT-tablet treatment was not associated with increased treatment-emergent adverse events (TEAEs), systemic allergic reactions, or severe local allergic swellings in adults or children with asthma, compared with those without asthma, in or outside of pollen season.
There were six out of 120 asthma-related TRAEs assessed as severe with SLIT tablet treatment and two out of 60 with placebo; the trend was consistent among those with and without asthma.
“In the AR/C subjects with reported well-controlled mild asthma included in these studies, grass SLIT-tablet did not increase TEAE frequency, severe local allergic swelling, or systemic allergic reactions versus subjects without asthma,” concluded the researchers.
Several authors disclosed financial ties (including employment) to pharmaceutical companies, including Merck & Co., which funded the study and manufactures MK-7243.